Alloy Therapeutics enters Japanese market by establishing operations at Shonan Health Innovation Park
US-based biotech ecosystems company establishes subsidiary in key Japanese market with launch of its first cell therapy base in Japan, a key modality for Alloy to fully advance its proprietary iCAR-T technology.
Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies
Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) provides external validation of Ypsilon’s platform and lead asset
Discovery of highly-specific TCR mimic antibodies to WT1
Navigating high homology: Discovery of TCR mimic antibodies with greater specificity to Wilms tumor 1 antigen The development of TCR mimic (TCRm) antibodies (or TCR-like antibodies) offers a promising new approach for cancer immunotherapy but identifying TCRm antibody candidates with optimal specificity and low off-target effects can be challenging. Here, we look at an antibody […]
Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
Boston, MA, January 9th, 2025 – Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new market-disrupting licensing structure. Partners can now have the option to use the ATX-GxTM antibody technology platform with no annual access fee or development milestones. […]
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
Boston, MA, January 7th, 2025 – Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi for a central nervous system (CNS) target. In return, […]
Discovering Antibodies in Months
Access the webinar recording Thanks for your interest in our recent antibody discovery webinar, Discovering Antibodies in Months: New Advances in HT-SPR, Single-Cell BCR-Seq and RNA-Seq. Alloy Head of Global Bioanalytics Dr. Lucy Liu presented on our workflow that improve the speed and quality of the antibody discovery process. Please fill out your contact information, and […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
Targeting GPCRs With DeepImmune™
AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms
Access the webinar recording Thanks for your interest in our recent AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording. Our approach Initiating antibody […]
